Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 1989 Mar 1;258(2):351–355. doi: 10.1042/bj2580351

Kallikrein stimulates arachidonic acid release and production of prostaglandins from TEA3A1 endocrine thymic epithelial cells.

L Sun 1, A Piltch 1, J Hayashi 1
PMCID: PMC1138368  PMID: 2495791

Abstract

Using TEA3A1 rat endocrine thymic epithelial cells, we demonstrated that kallikrein (EC 3.4.21.35) not only stimulated the release of arachidonic acid (AA) and its metabolites from TEA3A1 cells but also enhanced the intracellular synthesis of prostaglandin E2 (PGE2) and thromboxane B2 (TXB2) by approx. 2-fold. The stimulatory effect of kallikrein was dose- and time-dependent and could be blocked by aprotinin, a kallikrein inhibitor. It was found that the phospholipase A inhibitors ONO RS082 [2-(p-amylcinnamoyl)amino-4-chlorobenzoic acid], and mepacrine (6-chloro-9-[(4-dimethylamino)-1-methyl)]amino-2-methoxyacridine; quinacrine) also inhibited the kallikrein-stimulated release of AA and its metabolites. It is suggested that the kallikrein-induced stimulatory effect might be mediated through a phospholipase A2 pathway. The effect of bradykinin was studied and no significant stimulation was observed, even at a high dose (10 micrograms/ml). This suggested that the formation of kinin does not have a role in the kallikrein-induced stimulation of AA release from TEA3A1 cells. Furthermore, the effect of kallikrein was also totally abolished by adding pepstatin A, a known inhibitor of renin, pepsin and cathepsin D which does not inhibit kallikrein itself. This indicates that kallikrein did not act on the phospholipase-like enzyme directly. There is at least one more enzyme, a pepstatin A-inhibitable proteinase, that acts as a mediator for kallikrein-induced regulation of AA release.

Full text

PDF
351

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoyagi T., Suya H., Kato N., Nemoto O., Kobayashi H., Miura Y. Epidermal growth factor stimulates release of arachidonic acid in pig epidermis. J Invest Dermatol. 1985 Mar;84(3):168–171. doi: 10.1111/1523-1747.ep12264690. [DOI] [PubMed] [Google Scholar]
  2. Banga H. S., Simons E. R., Brass L. F., Rittenhouse S. E. Activation of phospholipases A and C in human platelets exposed to epinephrine: role of glycoproteins IIb/IIIa and dual role of epinephrine. Proc Natl Acad Sci U S A. 1986 Dec;83(23):9197–9201. doi: 10.1073/pnas.83.23.9197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bond J. S., Butler P. E. Intracellular proteases. Annu Rev Biochem. 1987;56:333–364. doi: 10.1146/annurev.bi.56.070187.002001. [DOI] [PubMed] [Google Scholar]
  4. Calvano S. E., Mark D. A., Good R. A., Fernandes G. Age-related changes in lymphoid tissue content of prostaglandins in (NZB X NZW)F1 and CBA/H mice. Arthritis Rheum. 1983 Jan;26(1):113–116. doi: 10.1002/art.1780260122. [DOI] [PubMed] [Google Scholar]
  5. Campbell W. B., Ojeda S. R. Measurement of prostaglandins by radioimmunoassay. Methods Enzymol. 1987;141:323–341. doi: 10.1016/0076-6879(87)41080-x. [DOI] [PubMed] [Google Scholar]
  6. Chouaib S., Welte K., Mertelsmann R., Dupont B. Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down-regulation of transferrin receptor expression. J Immunol. 1985 Aug;135(2):1172–1179. [PubMed] [Google Scholar]
  7. Dinarello C. A., Marnoy S. O., Rosenwasser L. J. Role of arachidonate metabolism in the immunoregulatory function of human leukocytic pyrogen/lymphocyte-activating factor/interleukin 1. J Immunol. 1983 Feb;130(2):890–895. [PubMed] [Google Scholar]
  8. Farrar W. L., Humes J. L. The role of arachidonic acid metabolism in the activities of interleukin 1 and 2. J Immunol. 1985 Aug;135(2):1153–1159. [PubMed] [Google Scholar]
  9. Goodwin J. S., Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol. 1983 Oct;3(4):295–315. doi: 10.1007/BF00915791. [DOI] [PubMed] [Google Scholar]
  10. Mertin J., Stackpoole A. Anti-PGE antibodies inhibit in vivo development of cell-mediated immunity. Nature. 1981 Dec 3;294(5840):456–458. doi: 10.1038/294456a0. [DOI] [PubMed] [Google Scholar]
  11. Morita I., Kanayasu T., Murota S. Kallikrein stimulates prostacyclin production in bovine vascular endothelial cells. Biochim Biophys Acta. 1984 Mar 7;792(3):304–309. [PubMed] [Google Scholar]
  12. Nasjletti A., Colina-Chourio J. Interaction of mineralocorticoids, renal prostaglandins and the renal kallikrein-kinin system. Fed Proc. 1976 Feb;35(2):189–193. [PubMed] [Google Scholar]
  13. Samuelsson B., Goldyne M., Granström E., Hamberg M., Hammarström S., Malmsten C. Prostaglandins and thromboxanes. Annu Rev Biochem. 1978;47:997–1029. doi: 10.1146/annurev.bi.47.070178.005025. [DOI] [PubMed] [Google Scholar]
  14. Simantov R., Sachs L. Role of phospholipase A2 and prostaglandin E in growth and differentiation of myeloid leukemic cells. Biochim Biophys Acta. 1982 Apr 29;720(2):111–119. doi: 10.1016/0167-4889(82)90001-5. [DOI] [PubMed] [Google Scholar]
  15. Walenga R., Vanderhoek J. Y., Feinstein M. B. Serine esterase inhibitors block stimulus-induced mobilization of arachidonic acid and phosphatidylinositide-specific phospholipase C activity in platelets. J Biol Chem. 1980 Jul 10;255(13):6024–6027. [PubMed] [Google Scholar]
  16. Whittum J., Goldschneider I., Greiner D., Zurier R. Developmental abnormalities of terminal deoxynucleotidyl transferase positive bone marrow cells and thymocytes in New Zealand mice: effects of prostaglandin E1. J Immunol. 1985 Jul;135(1):272–280. [PubMed] [Google Scholar]
  17. Zurier R. B. Prostaglandins, immune responses, and murine lupus. Arthritis Rheum. 1982 Jul;25(7):804–809. doi: 10.1002/art.1780250718. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES